niraparib + cetrelimab

**niraparib + cetrelimab** is an investigational, experimental combination of two drugs: niraparib, an orally active small molecule poly(ADP-ribose) polymerase (PARP) inhibitor, and cetrelimab, a fully human monoclonal antibody targeting the programmed death-1 (PD-1) receptor. Niraparib disrupts DNA repair in cancer cells with defects in homologous recombination, leading to cell death. Cetrelimab blocks PD-1 to activate T-cell–mediated immune responses against tumor cells. This combination is under clinical investigation for advanced, aggressive cancers, including aggressive variant prostate cancer (AVPC) and metastatic castration–resistant prostate cancer (mCRPC), particularly after prior chemotherapy. Clinical studies have shown improved progression-free and overall survival compared to niraparib alone in some settings but with increased toxicity[1][3].